EUCTR2007-003484-45-IT进行中（未招募）不适用
PHASE II TRIAL OF FOLFIRI REGIMEN PLUS BEVACIZUMAB ALTERNATED WITH OXALIPLATIN-BASED HEPATIC ARTERIAL INFUSION PLUS DE GRAMONT REGIMEN AND BEVACIZUMAB IN THE TREATMENT OF UNRESECTABLE LIVER METASTASES FROM COLORECTAL CANCER - ND
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •OLDER THAT 18 YEARS (PATIENTS >= YEARS OLD WILL UNDERGO MULTIDIMENSIONAL GERIATRIC ASSESSMENT), HISTOLOGICAL DIAGNOSIS OF CRC RADICALLY PREVIOUSLY RESECTED (METACHRONOUS LIVER METASTASIS) OR STILL IN PLACE (SYNCHRONOUS LIVER METASTASIS), UNRESECTABLE LIVEL METASTATIC DISEASE WITH LIVER PARENCHYMA REPLACEMENT LESS THAN TWO THIRDS, AS ASSESSED BY RADIOLOGICAL IMAGING (CT OR MRI SCANS), WRITTEN INFORMED CONSENT
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •METASTATIC DIFFUSION IN SITES DIFFERENT BY LIVER, PREVIOUS FIRST LINE THERAPY, RECENT MYOCARDIAL INFARCTION OR ACUTE HEARTH DISEASE, GASTRIC OR DUODENAL ULCER, RECENT SURGERY, ACTIVE SECOND NEOPLAM (WITH EXCEPTION OF SKIN AND IN-SITU CERVICAL TUMORS), SEVERE COGNITIVE IMPAIRMENT HAMPERING COMMUNICATIONS WITH THE PHYSICIAN
研究者
相似试验
已完成
2 期
Phase II trial of FOLFIRI plus Bevacizumab in second-line therapy after progression on bevacizumab with oxaliplatine-based chemotherapy in patients with metastatic colorectal cancer whose KRAS status are investigated.Recurrent or metastatic colorectal cancerJPRN-UMIN000004219Hyogo Cancer Center, Dept. of Gastrointestinal and Hepatobiliary Oncology40
招募中
2 期
A phase II trial of FOLFOXIRI+Bevacizumab as preoperative chemotherapy for locally advanced lower rectal cancerower rectal cancerJPRN-UMIN000031028Kobe University Graduate School of Medicine40
已完成
2 期
Phase II trial of FOLFOXIRI + Bevacizumab in patients with untreated metastatic colorectal cancerPatients with metastatic colorectal cancerJPRN-UMIN000017102Translational Research Informatics Center, Foundation for Biomedical Research and Innovation45
已完成
2 期
Phase II Study of FOLFIRI Plus Bevacizumab (AVASIRI) in Patients as Second Line Chemotherapy of Unresectable Colorectal CancerColorectal CancerJPRN-UMIN000001060ational Cancer Center Hospital, Gastrointestinal Oncology Division35
进行中（未招募）
不适用
PHASE II TRIAL OF FOLFOXIRI PLUS PANITUMUMAB AS FIRST-LINE TREATMENT FOR KRAS AND BRAF WILD-TYPE METASTATIC COLORECTAL CANCER - TRIPEUCTR2009-014556-29-ITG.O.N.O. - GRUPPO ONCOLOGICO NORD OVEST